Key result
Treatment with the adenosine analogue CADO significantly reduced heart to body weight ratio (6.80 vs 8.34 mg/g, P<0.0001) in mice with pressure-overload hypertrophy.
Why the study?
Does activation of adenosine A1 receptors attenuate cardiac hypertrophy and prevent heart failure in murine left ventricular pressure-overload models?
Does activation of adenosine A1 receptors attenuate cardiac hypertrophy and prevent heart failure in murine left ventricular pressure-overload models?
Absolute Event Rate: 6.8% vs 8.34%
p-value: p=<0.0001
Activation of adenosine A1 receptors attenuates cardiac hypertrophy and myocardial dysfunction in a murine pressure-overload model.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for A1 agonism in hypertrophy; leaves open translation to human pressure-overload HF.
Liao et al. (2003) studied Cardiac hypertrophy and heart failure. 2-chloroadenosine (CADO) and N6-cyclopentyladenosine (CPA) vs. Untreated TAC group was evaluated on Heart to body weight ratio (mg/g) (p=<0.0001). Treatment with the adenosine analogue CADO significantly reduced heart to body weight ratio (6.80 vs 8.34 mg/g, P<0.0001) in mice with pressure-overload hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: